Home
BCRX
BCRX News

Latest BioCryst Pharmaceuticals Inc. (BCRX) News on October 30, 2025

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

Insider Monkey

a month ago

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a month ago

BioCryst Pharmaceuticals Closes $250 Million Sale of Orladeyo Business in Europe

MT Newswires

a month ago

Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

GlobeNewswire

a month ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Investing.com

2 months ago

BofA lists 13 SMID cap stocks that could rebound

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire

2 months ago

BioCryst to Present at Upcoming Investor Conference

MT Newswires

4 months ago

Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating

MT Newswires

4 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires

4 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires

4 months ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid China Trade Deal Optimism

MT Newswires

4 months ago

BioCryst Pharmaceuticals to Sell European Orladeyo Business for up to $264 Million

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

GlobeNewswire

4 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

Zacks

4 months ago

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks

4 months ago

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

GlobeNewswire

4 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

MT Newswires

5 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Friday

MT Newswires

5 months ago

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia

ORLADEYO® (berotralstat) Approved in Colombia

GlobeNewswire

5 months ago

ORLADEYO® (berotralstat) Approved in Colombia

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

Zacks

5 months ago

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

MT Newswires

5 months ago

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

GlobeNewswire

5 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Zacks

5 months ago

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Best Momentum Stock to Buy for June 4th

Zacks

5 months ago

Best Momentum Stock to Buy for June 4th

New Strong Buy Stocks for June 4th

Zacks

5 months ago

New Strong Buy Stocks for June 4th

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

GlobeNewswire

5 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

GlobeNewswire

5 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

Zacks

5 months ago

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

5 months ago

BioCryst to Present at Upcoming Investor Conferences

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

MT Newswires

5 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires

5 months ago

BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

GlobeNewswire

5 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE

Pharmaceutical Technology

5 months ago

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE

MT Newswires

6 months ago

BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

GlobeNewswire

6 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

Best Momentum Stocks to Buy for May 9th

Zacks

6 months ago

Best Momentum Stocks to Buy for May 9th

Why BioCryst (BCRX) Might be Well Poised for a Surge

Zacks

6 months ago

Why BioCryst (BCRX) Might be Well Poised for a Surge

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?

Zacks

6 months ago

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

Zacks

6 months ago

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Simply Wall St.

6 months ago

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

MT Newswires

6 months ago

RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

Insider Monkey

6 months ago

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

GuruFocus.com

6 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

Thomson Reuters StreetEvents

6 months ago

Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

Zacks

6 months ago

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

MT Newswires

6 months ago

BioCryst Pharmaceuticals Reports Breakeven in Q1, Higher Revenue; Shares up Pre-Bell

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks To Watch In The US May 2025

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In The US May 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Appoints Steve Frank to Board of Directors

GlobeNewswire

6 months ago

BioCryst Appoints Steve Frank to Board of Directors

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

6 months ago

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

6 months ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Report First Quarter 2025 Financial Results on May 5

GlobeNewswire

6 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

Zacks

7 months ago

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

MT Newswires

7 months ago

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire

7 months ago

BioCryst to Present at Upcoming Investor Conference

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.

7 months ago

High Growth Tech Stocks In The US Market With Promising Potential

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Simply Wall St.

7 months ago

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

Insider Monkey

8 months ago

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

8 months ago

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Zacks

8 months ago

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Zacks

8 months ago

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Simply Wall St.

8 months ago

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Company News for Feb 25, 2025

Zacks

8 months ago

Company News for Feb 25, 2025

MT Newswires

8 months ago

RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

8 months ago

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Thomson Reuters StreetEvents

8 months ago

Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

GuruFocus.com

8 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Motley Fool

8 months ago

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

Motley Fool

8 months ago

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

8 months ago

BioCryst Says Interim Data Show Orladeyo Reduced Attack Rates in Pediatric Patients With Hereditary Angioedema

MT Newswires

8 months ago

BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows, Revenue Rises

Associated Press Finance

8 months ago

BioCryst: Q4 Earnings Snapshot

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

GlobeNewswire

8 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire

8 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

8 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

8 months ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MT Newswires

9 months ago

BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

GlobeNewswire

9 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

9 months ago

Exploring Three High Growth Tech Stocks In The United States

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

GlobeNewswire

9 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

GlobeNewswire

9 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

Simply Wall St.

9 months ago

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

BioCryst price target raised to $12 from $10 at Evercore ISI

TipRanks

10 months ago

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.

10 months ago

Exploring High Growth Tech Stocks In January 2025

MT Newswires

10 months ago

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire

10 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Simply Wall St.

10 months ago

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Share on Social Networks: